US Stock MarketDetailed Quotes
FGEN FibroGen
- 0.333
- -0.009-2.69%
Close Dec 13 16:00 ET
- 0.341
- +0.008+2.43%
Post 20:01 ET
33.55MMarket Cap-0.27P/E (TTM)
0.350High0.316Low1.11MVolume0.342Open0.342Pre Close361.77KTurnover1.19%Turnover RatioLossP/E (Static)100.77MShares2.93052wk High-0.14P/B30.97MFloat Cap0.18052wk Low--Dividend TTM93.03MShs Float68.550Historical High--Div YieldTTM9.85%Amplitude0.180Historical Low0.326Avg Price1Lot Size
FibroGen Stock Forum
Sign in to post a comment
$FibroGen (FGEN.US)$ I used to hold it during last year and my patience paid.
hope you can perform again 💪💪💪
hope you can perform again 💪💪💪
7
1
My guess is they are going to keep their doors open just long enough to sell off what little owning interest they have in the two remaining collaborative drug candidates
$FibroGen (FGEN.US)$ Officer Adib Deyaa purchased 22,123 shares of common stock on Jun 12, 2024 at an average price of $1.17 for a total value of $25,883.91.
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors.
FibroGen, Inc. (NASDAQ:FGEN) recently announced a milestone in its oncology pipeline. The U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for FG-3165, a novel galectin-9 (Gal9) targeted monoc...
FibroGen, Inc. (NASDAQ:FGEN) recently announced a milestone in its oncology pipeline. The U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for FG-3165, a novel galectin-9 (Gal9) targeted monoc...
$FibroGen (FGEN.US)$
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
FibroGen (NASDAQ: FGEN) announced FDA clearance for its Investigational New Drug (IND) application for FG-3165, a monoclonal antibody targeting galectin-9 (Gal9) for treating solid tumors. FG-3165 has shown anti-tumor activity and improved survival in preclinical models and exhibited excellent tol...
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
FibroGen (NASDAQ: FGEN) announced FDA clearance for its Investigational New Drug (IND) application for FG-3165, a monoclonal antibody targeting galectin-9 (Gal9) for treating solid tumors. FG-3165 has shown anti-tumor activity and improved survival in preclinical models and exhibited excellent tol...
3
No comment yet
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Coach Donnie : Let’s GOOO
Jenna Ragan OP Coach Donnie : it's a risk, but I've got a feeling about these guys.
Coach Donnie Jenna Ragan OP : Calculated risk. Mitigated. Congratulations
to us in advance cheers 
